I here certify that this carespondence First Class Mail in an excellope addresse on the date.

April 12, 2001

(0 A 0)

1652

I here certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an excellipe addressed to the Assistant Commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents, Washington, D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, on the date commissionel for Patents and D.C. 20231, o

By: Christine C. Gurney

PATENT Docket No. GC584-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	·
Wang, Huaming, et al.	Group Art Unit: Unassigned
Serial No.: 09/656,640)	Examiner: Unassigned
Filed: September 7, 2000	RECEIVED
For: Phenol Oxidizing Enzyme Variants)	APR 2 0 2001
Information Dis	TECH CENTER 1600/2900 sclosure Statement
Assistant Commissioner for Patents Washington, DC 20231	
Sir:	
Applicants submit herewith patents, publication	ons or other information (listed on the attached

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

on disclosure statement.
(a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
(b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
(c) as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.
(d) is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by

	in 37 C Accour Informa	the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified FR §1.97(e), as checked below. Authorization to charge Deposit at No. 07-1048 in the amount of \$180.00 to cover the cost of this ation Disclosure Statement is provided in the Transmittal Letter submitted th in duplicate.
	Transr No. 07 specific	is filed after the mailing date of either a final rejection or a notice of nce, whichever occurred first, and is accompanied by authorization (in the nittal Letter submitted herewith in duplicate) to charge Deposit Account -1048 the fee (\$180) set forth in 37 CFR §1.17(I)(1) and a certification as ed in 37 CFR §1.97(e), as checked below. This document is to be lered as a petition requesting consideration of the Supplemental nation Disclosure Statement.
[If either of b	oxes (d) or (e) is checked above, the following "certification" under 37 CFR
§1.97(e) may	need to	be completed.] The undersigned certifies that:
	counte	Each item of information contained in the Information Disclosure nent was cited in a communication mailed from a foreign patent office in a rpart foreign application not more than three months prior to the filing of ormation Disclosure Statement.
	foreign reason	No item of information contained in this Information Disclosure Statement ed in a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making able inquiry, was known to any individual designated in 37 CFR §1.56(c) and three months prior to the filing of this Information Disclosure tent.
A copy of the	items o	n Form PTO-1449 is supplied: PCT International Search Report for
PCT/US 00/24	1751, fil	ed 09/11/2000 with attached patents and publications.
⊠ eac	ch 🗌 n	one only those listed below:
PTO-1449 are	not suption, Se	blication(s) which are marked with an asterisk (*) on the attached Form oplied because they were previously cited by or submitted to the Office in the rial No filed, and relied upon in this application for an earlier filing 20.
A concise exp	lanatior	of relevance of the items listed on PTO-1449 is:
	\boxtimes	not given
		given for each listed item
		given for only non-English language listed item(s)

Serial No. 09/656,640 Page 3

in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: April 12, 2001

Registration No. 43,510

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7615 Fax: 650 845-6504